Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 33 clinical trials
Study of Daratumumab in Patients With Mild to Moderate Alzheimer's Disease (DARZAD)

This is an open-label, pilot study designed to explore whether daratumumab may have a clinically meaningful effect in patients with mild to moderate Alzheimer's disease.

memantine
alzheimer's disease
vitamin b12
cholinesterase
dementia
  • 132 views
  • 17 Feb, 2022
  • 1 location
MTX and Steroid for III-IV aGVHD Treatment

The aim of the study is to identify the efficacy and safety of methotrexate (MTX) combined corticosteroid treatment for grade III-IV acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT).

  • 0 views
  • 01 May, 2022
  • 1 location
MTX and Steroid as First-line Therapy for aGVHD

The aim of the study is to identify the efficacy and safety of methotrexate (MTX) combined corticosteroid as first-line therapy for acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (alloHSCT).

  • 0 views
  • 04 Oct, 2022
  • 1 location
Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL) (MABEL)

The subject has a type of cancer or lymph gland disease associated with a virus called Epstein Barr Virus (EBV), which has come back, is at risk of coming back, or has not gone away after standard treatments. This research study uses special immune system cells called LMP, BARF-1 and …

carcinoma
nasopharyngeal carcinoma
white blood cell count
pulse oximetry
immunosuppressive
  • 11 views
  • 24 Mar, 2022
  • 2 locations
Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma

Combination therapy is becoming more and more general in the treatment of oncological diseases. In this clinical trial combination the standard immunotherapeutic treatment; the programmed death 1 (PD-1) regulatory antibody Nivolumab and a peptide vaccine consisting of programmed death ligand 1 (PD-L1) and Indoleamine 2,3-dioxygenase (IDO) peptides will be tested …

  • 39 views
  • 07 Oct, 2022
  • 2 locations
The Efficacy and Safety of TACE Lenvatinib and Camrelizumab in the Treatment of BCLC Stage B/C Hepatocellular Carcinoma: a Single-arm Single-center Open-label Study

This study is a single-center, single-arm, open-label prospective clinical trial. By recording the disease-free progression (PFS), overall survival (OS) and tumor treatment response of the included patients, it is planned to evaluate TACE, lenvatinib and carrelizumab in the treatment of BCLC B/C hepatocytes Survival benefits of cancer patients; at the …

liver metastasis
neutrophil count
metastasis
platelet count
cancer
  • 0 views
  • 09 Jun, 2021
  • 1 location
Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma (IMA950-106)

Monocentric randomized phase I/II trial, including 24 patients diagnosed with relapsing glioblastoma (GBM) irrespective of MGMT and IDH gene status. Following diagnosis of relapsing glioblastoma by either brain CT scan or MRI, patients will be randomized in 2 arms: Arm 1: IMA950 mixed with Poly-ICLC administered subcutaneously Arm 2: Pembrolizumab …

measurable disease
poly iclc
dexamethasone
  • 48 views
  • 01 Feb, 2022
  • 1 location
A Single-center, Prospective, Single-arm Phase II Clinical Study on the Efficacy and Safety of TACE Combined With Camrelizumab and Apatinib in the Treatment of Advanced Liver Cancer

This study was designed to evaluate the effectiveness and safety of TACE(transcatheter arterial chemoembolization) combined with Apatinib and Camrelizumab for Hepatocellular Carcinoma. The primary outcome measure is to evaluate the objective response rate (ORR) of the therapy for Hepatocellular Carcinoma. The secondary Outcome measures include the duration of response (DOR), …

  • 0 views
  • 14 Oct, 2022
  • 1 location
Primary Hyperparathyroidism and Gut Microbiota (HYPOGEUM)

Primary hyperparathyroidism (PHPT) may induce bone loss according with the composition of the gut microbiota (GM), and particularly, on the presence of intestinal bacterial that induce T helper 17 differentiation. We will evaluate GM composition and evaluate how GM modulates immune system in patients affected by PHPT with or without …

  • 0 views
  • 15 Mar, 2022
  • 1 location
Evaluation of Splenic Metabolic Activity With 18FDG-PET in Hypertension

) or to immune profiles of activated T cells.

stroke
myocardial infarction
infarct
Accepts healthy volunteers
hypertension
  • 3 views
  • 24 Apr, 2022
  • 1 location